NIH’s IND for mitragynine cleared by the FDA on June 1, 2026, giving the agency a green light to run a phase‑I safety study.
Why Mitragynine?
Mitragynine is the main psychoactive alkaloid in Mitragyna speciosa (kratom). While kratom’s use as an opioid‑withdrawal aid has surged, the compound’s therapeutic potential hinges on its slow conversion in the body, which may dampen the typical abuse liability seen in other opioids.
Preclinical Safety Profile
Researchers at the University of Florida and NIH’s National Center for Advancing Translational Sciences (NCATS) tested multiple doses of purified mitragynine in animal models. Across all doses, no significant safety concerns emerged—no cardiotoxicity, no neurotoxicity, and no evidence of respiratory depression. These data satisfy the FDA’s safety thresholds for an IND.
Next Steps: Phase I Trial
The upcoming trial will be a randomized, double‑blind, placebo‑controlled study under the NIH HEAL Initiative. Investigators plan to enroll healthy volunteers and individuals with opioid use disorder, administering escalating doses of the purified formulation while monitoring vital signs, withdrawal scores, and pharmacokinetics. The primary endpoint is safety and tolerability; secondary endpoints will probe early signals of efficacy.
Implications for the Opioid Crisis
If mitragynine proves safe in humans, it could become a novel pharmacologic bridge for people tapering off prescription opioids or heroin. Unlike methadone or buprenorphine, mitragynine’s unique pharmacodynamics might reduce the risk of diversion and overdose. Moreover, the trial’s design—leveraging NIH’s HEAL Initiative—ensures rigorous oversight and rapid data sharing.
Looking Ahead
A successful phase‑I trial would unlock phase‑II studies focused on efficacy and dosing schedules. The NIH’s partnership with the University of Florida also positions the research for potential industry collaboration, accelerating the path from bench to bedside. In short, mitragynine’s IND approval marks the first concrete step toward a new, evidence‑based tool in the fight against opioid addiction.
Source: NIH research clears way for study of experimental treatment for opioid use disorder
Domain: nih.gov
Comments load interactively on the live page.